Eli Lilly and Company (LLY) to Release Quarterly Earnings on Tuesday

Eli Lilly and Company (NYSE:LLY) will be issuing its quarterly earnings data before the market opens on Tuesday, April 30th. Analysts expect the company to announce earnings of $2.61 per share for the quarter. Eli Lilly and Company has set its FY 2024 guidance at 12.200-12.700 EPS and its FY24 guidance at $12.20-12.70 EPS.Parties interested in registering for the company’s conference call can do so using this link.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The business had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the business posted $2.09 earnings per share. The firm’s quarterly revenue was up 28.1% on a year-over-year basis. On average, analysts expect Eli Lilly and Company to post $13 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Eli Lilly and Company Trading Up 0.7 %

Shares of NYSE:LLY opened at $731.32 on Tuesday. Eli Lilly and Company has a 12 month low of $370.68 and a 12 month high of $800.78. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. The company’s fifty day simple moving average is $763.83 and its 200 day simple moving average is $662.78. The firm has a market cap of $694.87 billion, a price-to-earnings ratio of 126.09, a PEG ratio of 1.58 and a beta of 0.34.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 78,573 shares of the business’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the completion of the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at approximately $64,375,262,246.70. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on LLY shares. Barclays lifted their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research report on Friday, March 8th. Citigroup lifted their price objective on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd. DZ Bank downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research report on Wednesday, February 21st. Finally, The Goldman Sachs Group lifted their price objective on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $728.05.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.